Current and future imaging techniques and recurrent prostate cancer

An article just reproduced on the Medscape Oncology web site provides a very readable review of what the authors describe as, “A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer”. … READ MORE …

Newer radio-tracer shows potential in imaging of recurrent prostate cancer

Data have been emerging for a while to suggest that a new imaging agent known as anti-3-[18F]FACBC (when used in PET/CT scans may be better than [11C]choline in the identification of recurrent (or primary) cancers on PET/CT scans or than older agents like [111In]capromab pendetide (Prostascint) when used in SPECT/CT scans. … READ MORE …

Use of imaging tests in low-risk prostate cancer — striking the right balance

An article published a couple of weeks ago in the Journal of the National Cancer Institute looks at the effects of a physician education campaign in Sweden to reduce the inappropriate use of bone scans and other imaging tests among men with an initial diagnosis of low-risk prostate cancer. … READ MORE …

“Multispectral photoacoustic imaging” for risk of prostate cancer

According to a media release issued earlier today by the University of Rochester Medical Center, “A new imaging technology that combines ultrasound and laser technologies has been shown to be highly effective in identifying prostate cancer.” … READ MORE …

mpMRI in diagnosis and management of prostate cancer tomorrow

A new review article in Oncology discusses the potential of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis and management of prostate cancer, and will be useful reading for many advocates and support group leaders. … READ MORE …

MRI-guided biopsies growing more common … but can we deal with the cost?

According to an article published on the Medscape Oncology web site earlier today, two paper presented at the European Congress of Radiology have provided further evidence of the potential of MRI-guided biopsies in the diagnosis of prostate cancer. … READ MORE …

New targeted imaging agents and the diagnosis, prognosis of progressive disease

According to a media release issued today by Progenics Pharmaceuticals, early clinical studies of two of their investigational products — the imaging agents [123I]-MIP-1072 and [123I]-MIP-1095 — suggest potential of these two agents in enhancement of imaging techniques to identify the exact location of cancer in bone, tissue, and the prostate itself. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers